Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261


Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder.

Liu JY, Li YH, Lin HX, Liao YJ, Mai SJ, Liu ZW, Zhang ZL, Jiang LJ, Zhang JX, Kung HF, Zeng YX, Zhou FJ, Xie D.

BMC Cancer. 2013 Jul 19;13:349. doi: 10.1186/1471-2407-13-349.


Argonaute 2 is up-regulated in tissues of urothelial carcinoma of bladder.

Yang FQ, Huang JH, Liu M, Yang FP, Li W, Wang GC, Che JP, Zheng JH.

Int J Clin Exp Pathol. 2013 Dec 15;7(1):340-7. eCollection 2014.


Bromodomain 4 protein is a predictor of survival for urothelial carcinoma of bladder.

Yan Y, Yang FQ, Zhang HM, Li J, Li W, Wang GC, Che JP, Zheng JH, Liu M.

Int J Clin Exp Pathol. 2014 Jun 15;7(7):4231-8. eCollection 2014.


High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma.

Li M, Luo RZ, Chen JW, Cao Y, Lu JB, He JH, Wu QL, Cai MY.

J Transl Med. 2011 Jan 5;9:5. doi: 10.1186/1479-5876-9-5.


Predictive value of Sox2 expression in transurethral resection specimens in patients with T1 bladder cancer.

Ruan J, Wei B, Xu Z, Yang S, Zhou Y, Yu M, Liang J, Jin K, Huang X, Lu P, Cheng H.

Med Oncol. 2013 Mar;30(1):445. doi: 10.1007/s12032-012-0445-z. Epub 2013 Jan 10.


CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma.

Xue Y, Wu G, Wang X, Zou X, Zhang G, Xiao R, Yuan Y, Long D, Yang J, Wu Y, Xu H, Liu F, Liu M.

Med Oncol. 2013 Mar;30(1):406. doi: 10.1007/s12032-012-0406-6. Epub 2012 Dec 30.


Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy.

Chen W, Luo JH, Hua WF, Zhou FJ, Lin MC, Kung HF, Zeng YX, Guan XY, Xie D.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):400-8. doi: 10.1158/1055-9965.EPI-08-0754. Epub 2009 Jan 20.


Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.

Bi J, Chen X, Zhang Y, Li B, Sun J, Shen H, Kong C.

Urol Oncol. 2012 Sep;30(5):688-94. doi: 10.1016/j.urolonc.2010.08.001. Epub 2010 Oct 2.


Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma.

Liang PI, Wu LC, Sheu JJ, Wu TF, Shen KH, Wang YH, Wu WR, Shiue YL, Huang HY, Hsu HP, Chen YH, Chen LT, Li CF, Liao AC.

J Clin Pathol. 2012 Sep;65(9):802-7. doi: 10.1136/jclinpath-2012-200897. Epub 2012 Jun 9.


PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer.

Yun SJ, Jo SW, Ha YS, Lee OJ, Kim WT, Kim YJ, Lee SC, Kim WJ.

Urol Oncol. 2012 Nov-Dec;30(6):893-9. doi: 10.1016/j.urolonc.2010.08.018. Epub 2011 Mar 10.


Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma.

Ke HL, Chang LL, Yang SF, Lin HH, Li CC, Wu DC, Wu WJ.

Urol Oncol. 2011 Nov-Dec;29(6):703-9. doi: 10.1016/j.urolonc.2009.10.009. Epub 2009 Dec 21.


Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer.

Otto W, Rubenwolf PC, Burger M, Fritsche HM, Rößler W, May M, Hartmann A, Hofstädter F, Wieland WF, Denzinger S.

BMC Cancer. 2012 Oct 8;12:459. doi: 10.1186/1471-2407-12-459.


CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer.

Xue YJ, Lu Q, Sun ZX.

Med Oncol. 2011 Dec;28(4):1363-72. doi: 10.1007/s12032-010-9582-4. Epub 2010 May 28.


Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival.

Luo JH, Xie D, Liu MZ, Chen W, Liu YD, Wu GQ, Kung HF, Zeng YX, Guan XY.

Int J Cancer. 2008 Jun 1;122(11):2554-61. doi: 10.1002/ijc.23399.


Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.

Kim JS, Chae Y, Ha YS, Kim IY, Byun SS, Yun SJ, Kim WJ.

Clin Genitourin Cancer. 2012 Jun;10(2):114-20. doi: 10.1016/j.clgc.2011.12.003. Epub 2012 Feb 28.


Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.

Nishikawa M, Miyake H, Behnsawy HM, Fujisawa M.

Urol Oncol. 2015 Apr;33(4):166.e9-15. doi: 10.1016/j.urolonc.2014.12.006. Epub 2015 Jan 21.


PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway.

Liu JY, Qian D, He LR, Li YH, Liao YJ, Mai SJ, Tian XP, Liu YH, Zhang JX, Kung HF, Zeng YX, Zhou FJ, Xie D.

Mol Cancer. 2013 Nov 23;12(1):148. doi: 10.1186/1476-4598-12-148.


An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.

Dickinson AJ, Fox SB, Newcomb PV, Persad RA, Sibley GN, Harris AL.

J Urol. 1995 Jul;154(1):237-41.


Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.

Caprodossi S, Lucciarini R, Amantini C, Nabissi M, Canesin G, Ballarini P, Di Spilimbergo A, Cardarelli MA, Servi L, Mammana G, Santoni G.

Eur Urol. 2008 Sep;54(3):612-20. Epub 2007 Oct 16.


Supplemental Content

Support Center